Obstetrics and Gynecology International / 2013 / Article / Tab 2 / Review Article
Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents Table 2 Main phase I-II clinical trials of various platinum combinations and non-platinum-containing regimens concurrently with external beam irradiation in patients with locally advanced cervical cancer.
Trial Year Phase Experimental regimen
FIGO stage Primary outcome Remarks Rao et al. [24 ] 2005 I Carboplatin 15 IB2-IVA Feasible 2-year PFS and OS were 80% and 86%, respectively Colombo et al. [27 ] 1997 II Carboplatin 28 IIA-IVA 5-year OS rate: 66% ORR, PFS, and OS not different to carboplatin alone Choi et al. [29 ] 2008 II Cisplatin 57 IB2-IVA 5-year OS rate: 70% ORR: 91.5% Sol et al. [30 ] 2009 II Cisplatin 93 IB-IVA 5-year PFS and OS were 79.1% and 80.9%, respectively Equally efficient but more toxic than cisplatin/5-FU Domingo et al. [32 ] 2009 II Capecitabine 60 IIB-IIIB ORR: 88% 1-year PFS and OS were 86% and 95%, respectively Zarbá et al. [34 ] 2003 I-II Gemcitabine 36 IIB-IVA 3-year OS rate: 72% 88.8% complete response rate Zhang et al. [35 ] 2010 II Paclitaxel Nedaplatin 34 IIB-IIIB 2-year OS: 93% 88% complete response rate Geara et al. [36 ] 2010 II Paclitaxel 31 IB2-IVA 5-year OS rate: 43% Inferior to weekly cisplatin Zanetta et al. [37 ] 2000 II Paclitaxel 38 Bulky locally advanced ORR: 84.2% Manageable toxicity Roberts et al. [38 ] 2000 II Mitomycin C 160 IB2-IVA 4-year PFS: 71% Better than radiotherapy alone Nguyen et al. [39 ] 1991 II Mitomycin C 38 IB-IVA Median OS: 87 months Significantly higher OS than 5-FU alone Christie et al. [40 ] 1995 II Mitomycin C 93 IB-IVA 73.2 4-year survival: 87% Berclaz et al. [41 ] 2002 II Cisplatin 22 IIB-IVA ORR: 82% All patients developed acute haematological toxicity Rose et al. [42 ] 2012 I Cisplatin Topotecan 11 IB-IVA Feasible Platinum dose reduced to 30 mg/m2 Fabbro et al. [43 ] 2010 I Cisplatin 15 IB2-IVA Feasible 2-year survival: 81%
FIGO: International Federation of Gynecologic Oncology; CRT: chemoradiotherapy; OS: overall survival; PFS: progression-free survival; ORR: objective response rate; 5-FU: 5-fluorouracil; PVI: protracted venous infusion;
: number of patients.
